Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players

Salvo Danilo Lombardo, Alessia Bramanti, Rosella Ciurleo, Maria Sofia Basile, Manuela Pennisi, Rita Bella, Katia Mangano, Placido Bramanti, Ferdinando Nicoletti, Paolo Fagone

Research output: Contribution to journalArticlepeer-review


Glioblastoma (GBM) represents the most frequent glial tumor, with almost 3 new cases per 100,000 people per year. Despite treatment, the prognosis for GBM patients remains extremely poor, with a median survival of 14.6 months, and a 5‑year survival less than 5%. It is generally believed that GBM creates a highly immunosuppressive microenvironment, sustained by the expression of immune‑regulatory factors, including inhibi‑ tory immune checkpoints, on both infiltrating cells and tumor cells. However, the trials assessing the efficacy of current immune checkpoint inhibitors in GBM are still disappointing. In the present study, the expression levels of several inhibitory immune checkpoints in GBM (CD276, VTCN1, CD47, PVR, TNFRSF14, CD200, LGALS9, NECTIN2 and CD48) were characterized in order to evaluate their potential as prognostic and eventually, therapeutic targets. Among the investigated immune checkpoints, TNFRSF14 and NECTIN2 were identified as the most promising targets in GBM. In particular, a higher TNFRSF14 expression was associated with worse overall survival and disease‑free survival, and with a lower Th1 response.

Original languageEnglish
Pages (from-to)332
JournalOncology Letters
Issue number6
Publication statusPublished - Oct 5 2020


  • Astrocytoma
  • CD200
  • CD276
  • CD47
  • CD48
  • Glioblastoma
  • Immune checkpoint
  • Inhibitory check‑ points
  • LGALS9
  • PVR
  • TNFRSF14
  • VTCN1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players'. Together they form a unique fingerprint.

Cite this